You are here:
Examining the Utility of In Vitro Bioactivity as a Conservative Point of Departure: A Case Study
Citation:
Paul-Friedman, K. AND R. Thomas. Examining the Utility of In Vitro Bioactivity as a Conservative Point of Departure: A Case Study. Presented at Office of Chemical Safety and Pollution Prevention (OCSPP) Visit to RTP June 2018, RTP, NC, June 08, 2018. https://doi.org/10.23645/epacomptox.6991130
Impact/Purpose:
Poster presentation to the EPA Office of Chemical Safety and Pollution Prevention (OCSPP) June 2018
Description:
In collaboration with partners from A*STAR, ECHA, EFSA, Health Canada, OECD-JRC, and other EPA offices, we want to test this hypothesis - that in vitro bioactivity can be used to derive a conservative point-of-departure (POD). Do new approach methods (NAMs; in vitro bioactivity data) provide a conservative estimate of POD compared to traditional in vivo data? Are bioactivity-exposure ratios (BER) useful for risk-based prioritization of chemicals for additional study and/or to serve as a low tier risk assessment approach? This poster gives an update of the latest findings of this group study.
URLs/Downloads:
DOI: Examining the Utility of In Vitro Bioactivity as a Conservative Point of Departure: A Case Study
POSTER_OCSPP_BIOACTIVITYASPOD_8JUN18.PDF (PDF, NA pp, 1575.747 KB, about PDF)